Biotech Values

[mcbio]

As for ghrelin antagonists, they usually target the GHS-R1A receptors, which are also growth hormone receptors (GH). You would want to be very careful with manipulation of this system. I know of one test with ghrelin antagonist in type 2 diabetic patients, that evaluates its effect on glucose homeostasis, but not anything with obesity.

What are your thoughts on ghrelin agonists? TZYM is developing ghrelin agonists towards GI disorders (lead drug is an IV towards POI and second drug in Phase 2 and is oral targeting diabetic gastroparesis, among other disorders). See: http://www.tranzyme.com/products .